Stifel Financial
BCRX icon

Stifel Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History

Stifel Financial’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.3M Buy
1,826,234
+1,050
+0.1% +$9.49K 0.02% 724
2026
Q1 		$17.4M Buy
1,825,184
+667
+0% +$5.18K 0.02% 690
2025
Q4 		$14.2M Buy
1,824,517
+1,525
+0.1% +$11K 0.01% 788
2025
Q3 		$13.8M Sell
1,822,992
-296
-0% -$2.46K 0.01% 794
2025
Q2 		$16.3M Sell
1,823,288
-13,691
-0.7% -$128K 0.02% 675
2025
Q1 		$13.8M Sell
1,836,979
-6,007
-0.3% -$48.5K 0.01% 717
2024
Q4 		$13.9M Sell
1,842,986
-303
-0% -$2.3K 0.01% 722
2024
Q3 		$14M Sell
1,843,289
-363
-0% -$2.76K 0.01% 727
2024
Q2 		$11.4M Sell
1,843,652
-284
-0% -$1.57K 0.01% 766
2024
Q1 		$9.37M Sell
1,843,936
-119
-0% -$669 0.01% 842
2023
Q4 		$11M Buy
1,844,055
+36
+0% +$209 0.01% 740
2023
Q3 		$13.1M Sell
1,844,019
-535
-0% -$3.84K 0.02% 623
2023
Q2 		$13M Buy
1,844,554
+480
+0% +$3.85K 0.02% 618
2023
Q1 		$15.4M Hold
1,844,074
– – 0.02% 537
2022
Q4 		$21.2M Sell
1,844,074
-2,100
-0.1% -$26.2K 0.03% 435
2022
Q3 		$23.3M Sell
1,846,174
-3,850
-0.2% -$49.5K 0.04% 392
2022
Q2 		$19.6M Sell
1,850,024
-318
-0% -$3.28K 0.03% 457
2022
Q1 		$30.1M Buy
1,850,342
+818
+0% +$13.1K 0.04% 372
2021
Q4 		$25.6M Sell
1,849,524
-830
-0% -$11K 0.03% 426
2021
Q3 		$26.6M Hold
1,850,354
– – 0.04% 391
2021
Q2 		$29.3M Hold
1,850,354
– – 0.04% 345
2021
Q1 		$18.8M Sell
1,850,354
-191,745
-9% -$1.98M 0.03% 447
2020
Q4 		$15.2M Hold
2,042,099
– – 0.03% 476
2020
Q3 		$7.01M Hold
2,042,099
– – 0.01% 649
2020
Q2 		$9.73M Sell
2,042,099
-49,170
-2% -$196K 0.02% 513
2020
Q1 		$4.18M Buy
+2,091,269
New +$5.76M 0.01% 726

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Stifel Financial's BCRX Position: Q2 2026 in Review

Stifel Financial increased its BioCryst Pharmaceuticals (BCRX) stake by 0.06% in Q2 2026, buying an estimated $9.49K and bringing the position to 1,826,234 shares worth $18.3M. The position accounts for 0.02% of the portfolio, ranked #724.

Stifel Financial first reported a position in BCRX in Q1 2020 and has held it in 26 quarters since. The position peaked at $30.1M in Q1 2022. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Stifel Financial held 1,826,234 shares of BioCryst Pharmaceuticals worth $18.3M as of Q2 2026.
  • Stifel Financial bought 1,050 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $9.49K.
  • BioCryst Pharmaceuticals made up 0.02% of Stifel Financial's portfolio in Q2 2026, its #724 holding.
  • Stifel Financial first reported a position in BioCryst Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Stifel Financial's BioCryst Pharmaceuticals position peaked at $30.1M in Q1 2022.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.